close

GlaxoSmithKline plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, over the counter (OTC) medicines, and health related consumer products. It operates in two segments, Pharmaceutical and Consumer Healthcare. The Pharmaceutical segment offers prescription medicines in the therapeutic areas, such as respiratory, central nervous system, anti-virals, anti-bacterials, metabolic, vaccines, cardiovascular and urogenital, oncology, emesis, and dermatology. This segment markets approximately 25 vaccines to prevent life-threatening or crippling illnesses, such as hepatitis A, hepatitis B, diphtheria, tetanus, whooping cough, measles, mumps, rubella, polio, typhoid, influenza, and bacterial meningitis. The Consumer Healthcare segment offers OTC medicines, such as alli, a weight loss medicine; Panadol, a paracetamol/acetaminophen analgesic; smoking control products under the NicoDerm, NiQuitin CQ, Nicabate, and Nicorette names; and other brands, including Breathe Right nasal strips, Tums, Citrucel, Contac, and FiberChoice. Its oral healthcare products comprise Aquafresh, a range of toothpastes, toothbrushes, and mouthwashes; Sensodyne, a range of toothpastes and toothbrushes, including Pronamel to protect from acid erosion; Biotene, a treatment for dry mouth; Polident, PoliGrip, and Corega, the denture care cleansers and adhesives; and other brands, including Odol, Macleans, and Dr Best. This segment also provides nutritional healthcare products, such as Lucozade, a range of energy and sports drinks; Horlicks, a range of milk-based malted food and chocolate drinks; and Ribena, a blackcurrant juice-based drink. GlaxoSmithKline operates in the United States, Europe, Japan, the Asia Pacific, the Middle East, Latin America, Africa, and Canada. The company was founded in 1935 and is based in Brentford, the United Kingdom.

(login to add this stock to your watchlist or favorites)

Key Statistics

Closing Price	45.03
Volume	(mio) 2.08
Volume Avg	(mio) 2.27
52 Week High	46.50
52 Week Low	36.39
PE	28.17
PE (group average)	39
EPS Year	1.61
EPS change Q/Q	-1000%
EPS change Q/Q Yr ago	11.63%
EPS change Q/Q next Q est	-48.39%
EPS change Y/Y	222.81%
REV change Q/Q	-9.09%
REV change Q/Q Yr ago	-9.09%
EPS next Q est	0.93
EPS next Y est	4.30
Divident Annual	2.41
Dividend Yield	5.35%